CÔNG TY CP DƯỢC LÂM ĐỒNG (LADOPHAR)
LAM DONG PHARMACEUTICAL JOINT STOCK COMPANY

CỘNG HOÀ XÃ HỘI CHỦ NGHĨA VIỆT NAM
Độc lập - Tự do - Hạnh phúc
THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom - Happiness

Số/No: 21/CBTT-LDP/2026

Lâm Đồng, ngày 26 tháng 07 năm 2026
Lam Dong, July 26 , 2026

CÔNG BỐ THÔNG TIN BẤT THƯỜNG
EXTRAORDINARY INFORMATION DISCLOSURE

Kính gửi: - Ủy ban Chứng khoán Nhà nước;
- Sở Giao dịch Chứng khoán Hà Nội.

To: - State Securities Commission;
- Hanoi Stock Exchange.

1. Tên tổ chức/Name of organization: CÔNG TY CP DƯỢC LÂM ĐỒNG (LADOPHAR)/ *LAM DONG PHARMACEUTICAL JOINT STOCK COMPANY*
- Mã chứng khoán/*Stock code*: LDP
- Địa chỉ/*Address*: Số 18 Ngô Quyền, Phường Cam Ly - Đà Lạt, Tỉnh Lâm Đồng/No. *18 Ngo Quyen Road, Ward CamLy – Dalat, Lam Dong Province.*
- Điện thoại liên hệ/*Tel*: (84-263) 3821228 – 3817937
- E-mail: thukyhdqt@ladophar.com

2. Nội dung thông tin công bố/*Contents of disclosure*:

Công ty CP Dược Lâm Đồng (Ladophar) công bố thông tin công văn biện pháp và lộ trình khắc phục tình trạng chứng khoán LDP bị cảnh báo.

Lam Dong Pharmaceutical Joint Stock Company (Ladophar) Announcement of the official dispatch on measures and roadmap to remedy the situation of LDP securities being warned.

3. Thông tin này đã được công bố trên trang thông tin điện tử của Công ty vào ngày 26/07/2026 tại đường dẫn https://ladophar.com/quan-he-co-dong/

This information was published on the company's website on July 26, 2026, as in the links https://ladophar.com/quan-he-co-dong

Chúng tôi xin cam kết các thông tin công bố trên đây là đúng sự thật và hoàn toàn chịu trách nhiệm trước pháp luật về nội dung các thông tin đã công bố/

We hereby certify that the information provided is true and correct and we bear the full responsibility to the law./.

Tài liệu đính kèm/*Attached documents*:

Công văn số 17/CV-HĐQT/LDP/2026 ngày 25/07/2026/

Judgment No.: 17/CVHĐQT/LDP/2026 dated July 25, 2026

Nơi nhận:

- Như trên/*As above*;
- Lưu: TKHĐQT, VP/ *Secretariat, LDP Office*.

ĐẠI DIỆN TỔ CHỨC

NGƯỜI ĐẠI DIỆN THEO PHÁP LUẬT

CHỦ TỊCH HỘI ĐỒNG QUẢN TRỊ

ORGANIZATION REPRESENTATIVE

LEGAL REPRESENTATIVE

CHAIRMAN OF THE BOARD OF DIRECTORS

PHẠM TRUNG KIÊN

LADOPHAR
TINH HOA DƯỢC LIỆU

CÔNG TY CP DƯỢC LÂM ĐỒNG (LADOPHAR)
Số 18 Ngô Quyền, Phường Cam Ly - Đà Lạt, Tỉnh Lâm Đồng
Hotline: 0263.999.9999 Email: info@ladophar.com Website: www.ladophar.com

No.: 17/CV-HĐQT/LDP/2026
Re: Remedial measures and roadmap to address the warning.

Lam Dong, July 25, 2026

To: Hanoi Stock Exchange

Lam Dong Pharmaceutical Joint Stock Company (Ladophar) would like to extend to the Hanoi Stock Exchange (HNX) our respectful greetings and sincere thanks for your attention and support over the past period.

Pursuant to the Decisions and Notices issued by HNX regarding the Company's LDP shares, including:

- *Notice No. 2947/TB-SGDHN dated 07/07/2026 of the Hanoi Stock Exchange on the trading status of LDP shares;*
- *Decision No. 884/QĐ-SGDHN dated 07/07/2026 of the Hanoi Stock Exchange on maintaining the warning status of the shares.*

The Company would like to present the remedial measures and roadmap to address the warning status of its securities as follows:

1. Report on the implementation status of remedial measures

In the first 6 months of 2026, the Company achieved positive results compared to the same period last year:

- Total revenue from goods and services increased by VND 18 billion (up 16%), of which revenue from manufactured products increased by VND 11.5 billion and revenue from trading goods increased by VND 6.5 billion
- Net revenue reached VND 129,079 million, up approximately 16% year-on-year (revenue from both manufactured and trading goods increased).
- Gross profit reached VND 48,476 million, up 32% year-on-year.
- Profit before tax for the first 6 months reached VND 4,713 million, up VND 2.5 billion (equivalent to an increase of 110% year-on-year).
- Profit after tax reached VND 1,761 million.

The above results show that the Company's business operations are recovering strongly, contributing to the improvement of undistributed profit and gradually addressing the causes that led to the warning status.

2. Specific remedial measures:

The Company will comprehensively implement the 2026 Business Plan and focus on simultaneously addressing both the warning and control statuses through the following groups of solutions:

a. Addressing the cause of the control status (qualified audit opinion):

- Continue to closely coordinate with the judgment enforcement authority to recover the assets of Bao Thu Industrial Investment and Development Joint Stock Company.
- Closely coordinate with the auditor so that the 2026 consolidated financial statements receive an unqualified (unmodified) opinion.

b. Addressing the causes of the warning status (maintaining positive undistributed profit and holding the 2026 Annual General Meeting of Shareholders):

- Convene the 2026 Annual General Meeting of Shareholders: the shareholder list record date was finalized on 22/07/2026, with the meeting expected to be held in August 2026 at the head office in Da Lat.
- Synchronously implement solutions to boost sales growth in accordance with the 2026 Business Plan (targeting total revenue of VND 324.9 billion):
    - Strengthen strategic sales channels: Increase penetration of the ETC channel (hospital tenders), expand the pharmacy and supermarket chain network; strongly develop e-commerce and exports (Artichoke and Red Artichoke/Roselle to ASEAN markets and other new markets).
    - Optimize the product portfolio: Focus on strengthening product groups with high profit margins, while developing new products from Vietnamese medicinal herbs in line with the orientation of “modern health from Vietnamese herbal medicine”.
    - Effective cost control: Save on selling expenses and administrative expenses, optimize logistics and marketing costs; strictly control financial expenses (including provisions for doubtful debts and bond interest).
    - Strengthen support activities: Step up marketing and Ladophar brand building; enhance production capacity; complete the KPI system and authorization regulations; organize internal training to improve staff capability.
    - Manage risks and related-party transactions: closely supervise transactions with related parties, ensuring compliance with information disclosure regulations.

3. Roadmap and expected targets from Q2 to Q4 2026

- August 2026: Convene the 2026 Annual General Meeting of Shareholders
- Q3 – Q4/2026: Step up production and business activities, finalize the 2026 financial statements with a clean (unqualified) audit opinion.

- By the end of 2026: Ensure completion of the plan's targets and consolidate positive undistributed profit.

If the above targets are achieved, the Company will submit an official request to the Exchange and the State Securities Commission (SSC) to consider removing the warning and control status starting from Q1/2027.

Risks have been controlled through diversification of supply sources, long-term contracts, and strict management of related-party transactions.

The Company commits that all information provided is true and accurate and takes legal responsibility therefor. We look forward to receiving further support and guidance from the Exchange and the SSC.

Sincerely thank you and best regards./.

LEGAL REPRESENTATIVE
CHAIRMAN OF THE BOARD OF DIRECTORS

M.S.D.N: 5800000047 - C.T.C.P ★ CÔNG TY CP DƯỢC LÂM ĐỒNG (LADOPHAR) P. CAM LY - ĐÀ LẠT, T. LÂM ĐỒNG

PHẠM TRUNG KIÊN

Recipients:
-As addressed above;
-Board of Directors, Supervisory Board (for reporting);
- Filed: Administration Office (VT).